Precigen’s (PGEN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Precigen (NASDAQ:PGEN) in a research note released on Monday morning, MarketBeat Ratings reports. HC Wainwright currently has a $14.00 price objective on the biotechnology company’s stock.

Several other research firms also recently weighed in on PGEN. Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Finally, Citizens Jmp increased their price target on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $14.50.

Precigen Trading Up 5.5%

NASDAQ:PGEN opened at $6.89 on Monday. The company has a market capitalization of $2.46 billion, a P/E ratio of -6.62 and a beta of 1.02. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62. Precigen has a 12 month low of $1.70 and a 12 month high of $7.23. The firm has a fifty day simple moving average of $5.12 and a 200-day simple moving average of $4.46.

Precigen (NASDAQ:PGEN) last released its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.06. The firm had revenue of $54.98 million for the quarter, compared to the consensus estimate of $27.98 million. Precigen had a positive return on equity of 484.64% and a negative net margin of 183.98%.The firm’s revenue was up 6322.7% on a year-over-year basis. On average, equities research analysts anticipate that Precigen will post -0.02 earnings per share for the current year.

Insider Buying and Selling at Precigen

In other Precigen news, COO Rutul R. Shah sold 33,772 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $6.50, for a total transaction of $219,518.00. Following the sale, the chief operating officer directly owned 497,751 shares of the company’s stock, valued at approximately $3,235,381.50. This trade represents a 6.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Donald P. Lehr sold 29,131 shares of Precigen stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $4.36, for a total value of $127,011.16. Following the transaction, the insider owned 755,461 shares of the company’s stock, valued at $3,293,809.96. The trade was a 3.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 956,500 shares of company stock valued at $5,248,371 in the last three months. Company insiders own 41.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. State of Wyoming purchased a new stake in Precigen in the 1st quarter worth approximately $27,000. NBC Securities Inc. purchased a new position in shares of Precigen during the 4th quarter valued at approximately $38,000. Mason Investment Advisory Services Inc. acquired a new position in shares of Precigen in the 4th quarter valued at $42,000. Abel Hall LLC acquired a new position in shares of Precigen in the 4th quarter valued at $44,000. Finally, Royal Bank of Canada boosted its holdings in Precigen by 102.6% during the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,426 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen News Roundup

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 earnings beat: Precigen reported $54.98 million in revenue, far above the roughly $28 million analyst consensus, while earnings were $0.05 per share versus expectations for a loss of approximately $0.01–$0.02. Revenue increased sharply year over year, and the company posted $20.1 million in net income attributable to common shareholders. Precigen Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: PAPZIMEOS momentum is driving the business: PAPZIMEOS generated $53.1 million of Q2 net revenue, more than double the prior quarter. Patient-hub enrollment exceeded 500, and FDA-granted seven-year market exclusivity strengthens the product’s commercial outlook. Management said current resources and product revenue are expected to support cash-flow break-even by the end of 2026. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst support remains favorable: HC Wainwright reiterated its Buy rating and $14 price target, well above recent trading levels. The firm’s endorsement reinforced the bullish reaction to the earnings report. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusually heavy options activity suggests increased investor attention and potentially higher near-term volatility, but the report does not establish whether options traders are primarily bullish or bearish. Precigen Target of Unusually Large Options Trading
• Negative Sentiment: Insider selling is a counterpoint: Precigen executives, including the COO, CEO and CFO, have reported stock sales, with no insider purchases cited over the past six months. The latest COO sale was made under a pre-arranged Rule 10b5-1 plan, reducing its informational significance but still presenting a potential overhang. Precigen Insider Selling

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.